The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

References

• American Cancer SocietyCancer Facts and Figures 2016AtlantaGACS
   Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non–small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• TchekmedyianNAliSMMillerVAHauraEBAcquired ALK L1152R mutation confers resistance to ceritinib and predicts response to alectinibJ Thorac Oncol201611e87e8827091190
   PubMed Web of Science ®Google Scholar
• KatayamaRLovlyCMShawATTherapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicineClin Cancer Res201521102227223525979929
   PubMed Web of Science ®Google Scholar
• IsozakiHTakigawaNKiuraKMechanisms of aacquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancerCancers (Basel)20157276378325941796
   PubMedGoogle Scholar
• ZhangSAnjumRSquillaceRThe potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical modelsClin Cancer Res201622225527553827780853
   PubMed Web of Science ®Google Scholar
• ShakespeareWFantinVWangFAbstract #3738: discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)Cancer Res20096937383738
   Web of Science ®Google Scholar
• HuangQJohnsonTWBaileySDesign of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibJ Med Chem20145741170118724432909
   PubMed Web of Science ®Google Scholar
• HuangWLiuSZouDDiscovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinaseJ Med Chem201659104948496427144831
   PubMed Web of Science ®Google Scholar
• RiveraVMWangFAnjumRAbstract 1794: AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLCCancer Res20147217941794
   Web of Science ®Google Scholar
• SquillaceRMAnjumRMillerDAbstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusionsCancer Res201473856555655
   Google Scholar
• ZhangSWangFKeatsJAbstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (F1066)Cancer Res2014708LB-298LB-298
   Google Scholar
• RiveraVMAnjumRWangFAbstract 3623: efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)Cancer Res201070836233623
   Google Scholar
• GettingerSNBazhenovaLALangerCJActivity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialLancet Oncol201617121683169627836716
   PubMed Web of Science ®Google Scholar
• Ross CamidgeDTiseoMAhnMyung-JuBrigatinib in Crizotinib-Refractory ALK+NSCLC: central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: World Conference on Lung Cancer 2016 Poster 40462016
   Google Scholar
• Dong-Wan KimMTCamidgeD RossBrigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): first report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). Abstract 9007 ASCO 2016J Clin Oncol201634Suppl abstr 9007
   Google Scholar
• GettingerSNZhangSHodgsonJGActivity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status. ASCO 2016 Abstract 9060J Clin Oncol201634Suppl abstr 9060
   Google Scholar
• GainorJFDardaeiLYodaSMolecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancerCancer Discov20166101118113327432227
   PubMed Web of Science ®Google Scholar
• NokiharaHHidaTKondoMAlectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study. Abstract 9008 ASCO 2016J Clin Oncol201634Suppl abstr 9008
   Google Scholar
• ShawATFribouletLLeshchinerIResensitization to crizotinib by the lorlatinib ALK resistance mutation L1198FN Engl J Med20163741546126698910
   PubMed Web of Science ®Google Scholar
• ShawATGandhiLGadgeelSAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialLancet Oncol201617223424226708155
   PubMed Web of Science ®Google Scholar
• OuSHAhnJSDe PetrisAlectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global studyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• KimDWMehraRTanDSActivity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialLancet Oncol20161745246326973324
   PubMed Web of Science ®Google Scholar
• MokTSpiegelDFelipEASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Abstract 8059 ASC0 Annual Meeting 2015J Clin Oncol201533Suppl abstr 8059
   Google Scholar
• ZhangSNadwornySScottDAbstract 781: the potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first-and second-generation ALK TKIs in preclinical modelsCancer Res20157515781781
   Google Scholar